

John F Tisdale

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6480123/publications.pdf>

Version: 2024-02-01

139
papers

4,949
citations

126858

33
h-index

110317

64
g-index

141
all docs

141
docs citations

141
times ranked

4258
citing authors

#	ARTICLE	IF	CITATIONS
1	Towards access for all: 1st Working Group Report for the Global Gene Therapy Initiative (GGTI). <i>Gene Therapy</i> , 2023, 30, 216-221.	2.3	6
2	Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease. <i>New England Journal of Medicine</i> , 2022, 386, 617-628.	13.9	144
3	Acute Myeloid Leukemia Case after Gene Therapy for Sickle Cell Disease. <i>New England Journal of Medicine</i> , 2022, 386, 138-147.	13.9	86
4	Safety of liver biopsy in patients with sickle cell related liver disease: A single-center experience. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	1
5	A macaque clonal hematopoiesis model demonstrates expansion of TET2-disrupted clones and utility for testing interventions. <i>Blood</i> , 2022, 140, 1774-1789.	0.6	13
6	Optimizing haematopoietic stem and progenitor cell apheresis collection from plerixafor-mobilized patients with sickle cell disease. <i>British Journal of Haematology</i> , 2022, 198, 740-744.	1.2	8
7	Gene Therapy for Hemoglobinopathies. <i>Hematology/Oncology Clinics of North America</i> , 2022, 36, 769-795.	0.9	9
8	Dietary iron restriction improves markers of disease severity in murine sickle cell anemia. <i>Blood</i> , 2021, 137, 1553-1555.	0.6	14
9	Commentary on Winzeler et al "Low arginine vasopressin levels in patients with diabetes insipidus are not associated with anaemia". <i>Clinical Endocrinology</i> , 2021, 94, 888-890.	1.2	1
10	Non-myeloablative human leukocyte antigen-matched related donor transplantation in sickle cell disease: outcomes from three independent centres. <i>British Journal of Haematology</i> , 2021, 192, 761-768.	1.2	41
11	Hematopoietic Stem Cell-Targeted Gene-Addition and Gene-Editing Strategies for β^2 -hemoglobinopathies. <i>Cell Stem Cell</i> , 2021, 28, 191-208.	5.2	17
12	Sustained fetal hemoglobin induction in vivo is achieved by <i>BCL11A</i> interference and coexpressed truncated erythropoietin receptor. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	6
13	A pause in gene therapy: Reflecting on the unique challenges of sickle cell disease. <i>Molecular Therapy</i> , 2021, 29, 1355-1356.	3.7	29
14	Preclinical evaluation for engraftment of CD34+ cells gene-edited at the sickle cell disease locus in xenograft mouse and non-human primate models. <i>Cell Reports Medicine</i> , 2021, 2, 100247.	3.3	15
15	Genetic therapies for the first molecular disease. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	17
16	Disease severity impacts plerixafor-mobilized stem cell collection in patients with sickle cell disease. <i>Blood Advances</i> , 2021, 5, 2403-2411.	2.5	24
17	Base editing of haematopoietic stem cells rescues sickle cell disease in mice. <i>Nature</i> , 2021, 595, 295-302.	13.7	175
18	Cas9 protein delivery non-integrating lentiviral vectors for gene correction in sickle cell disease. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 21, 121-132.	1.8	25

#	ARTICLE	IF	CITATIONS
19	Development of β^2 -globin gene correction in human hematopoietic stem cells as a potential durable treatment for sickle cell disease. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	82
20	Gene therapy for sickle cell disease: moving from the bench to the bedside. <i>Blood</i> , 2021, 138, 932-941.	0.6	37
21	Increased Rates of Rhabdomyolysis in Male Hematopoietic Cell Transplantation Recipients Taking Sirolimus and Trimethoprim/Sulfamethoxazole. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 1019.e1-1019.e4.	0.6	2
22	American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation. <i>Blood Advances</i> , 2021, 5, 3668-3689.	2.5	38
23	CRISPR-Cas9 to induce fetal hemoglobin for the treatment of sickle cell disease. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 23, 276-285.	1.8	13
24	Neurocognitive functioning in symptomatic adults with sickle cell disease: A description and comparison with unaffected siblings. <i>Neuropsychological Rehabilitation</i> , 2020, 30, 1666-1681.	1.0	11
25	Immunoresponse to Gene-Modified Hematopoietic Stem Cells. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 16, 42-49.	1.8	16
26	Definitive hematopoietic stem/progenitor cells from human embryonic stem cells through serum/feeder-free organoid-induced differentiation. <i>Stem Cell Research and Therapy</i> , 2020, 11, 493.	2.4	13
27	Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease. <i>Blood Advances</i> , 2020, 4, 2058-2063.	2.5	93
28	Hematopoietic stem cells from pluripotent stem cells: Clinical potential, challenges, and future perspectives. <i>Stem Cells Translational Medicine</i> , 2020, 9, 1549-1557.	1.6	43
29	Safety and feasibility of hematopoietic progenitor stem cell collection by mobilization with plerixafor followed by apheresis vs bone marrow harvest in patients with sickle cell disease in the multi-center <scp>HGB</scp> trial. <i>American Journal of Hematology</i> , 2020, 95, E239-E242.	2.0	22
30	Genome editing strategies for fetal hemoglobin induction in beta-hemoglobinopathies. <i>Human Molecular Genetics</i> , 2020, 29, R100-R106.	1.4	15
31	β^2 T87Q-Globin Gene Therapy Reduces Sickle Hemoglobin Production, Allowing for Ex Vivo Anti-sickling Activity in Human Erythroid Cells. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 17, 912-921.	1.8	13
32	Safe and efficient peripheral blood stem cell collection in patients with sickle cell disease using plerixafor. <i>Haematologica</i> , 2020, 105, e497.	1.7	29
33	Biallelic correction of sickle cell disease-derived induced pluripotent stem cells (iPSCs) confirmed at the protein level through serum-free iPSCsac/erythroid differentiation. <i>Stem Cells Translational Medicine</i> , 2020, 9, 590-602.	1.6	17
34	Curative options for sickle cell disease: haploidentical stem cell transplantation or gene therapy?. <i>British Journal of Haematology</i> , 2020, 189, 408-423.	1.2	29
35	BCL11A enhancer-edited hematopoietic stem cells persist in rhesus monkeys without toxicity. <i>Journal of Clinical Investigation</i> , 2020, 130, 6677-6687.	3.9	54
36	Intrabone transplantation of CD34+ cells with optimized delivery does not enhance engraftment in a rhesus macaque model. <i>Blood Advances</i> , 2020, 4, 6148-6156.	2.5	5

#	ARTICLE	IF	CITATIONS
37	Busulfan Combined with Immunosuppression Allows Efficient Engraftment of Gene-Modified Cells in a Rhesus Macaque Model. <i>Molecular Therapy</i> , 2019, 27, 1586-1596.	3.7	28
38	Robust generation of erythroid and multilineage hematopoietic progenitors from human iPSCs using a scalable monolayer culture system. <i>Stem Cell Research</i> , 2019, 41, 101600.	0.3	23
39	Development of a forward-oriented therapeutic lentiviral vector for hemoglobin disorders. <i>Nature Communications</i> , 2019, 10, 4479.	5.8	21
40	CRISPR/Cas9 for Sickle Cell Disease: Applications, Future Possibilities, and Challenges. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1144, 37-52.	0.8	37
41	Vibration Controlled Transient Elastography (Fibroscan®) in sickle cell liver disease –could we strike while the liver is hard?. <i>British Journal of Haematology</i> , 2019, 187, 117-123.	1.2	6
42	Fetal hemoglobin and F-cell variance in mobilized CD34+ cell-transplanted rhesus monkeys. <i>Experimental Hematology</i> , 2019, 75, 21-25.e1.	0.2	3
43	Aberrant Clonal Hematopoiesis following Lentiviral Vector Transduction of HSPCs in a Rhesus Macaque. <i>Molecular Therapy</i> , 2019, 27, 1074-1086.	3.7	34
44	High-Efficiency Lentiviral Transduction of Human CD34+ Cells in High-Density Culture with Poloxamer and Prostaglandin E2. <i>Molecular Therapy - Methods and Clinical Development</i> , 2019, 13, 187-196.	1.8	31
45	Improvements in haploidentical transplantation for sickle cell disease and β^0 -thalassaemia. <i>Lancet Haematology</i> , 2019, 6, e168-e169.	2.2	6
46	Bone marrow characterization in sickle cell disease: inflammation and stress erythropoiesis lead to suboptimal CD34 recovery. <i>British Journal of Haematology</i> , 2019, 186, 286-299.	1.2	49
47	Lentiglobin Gene Therapy in Patients with Sickle Cell Disease: Updated Interim Results from Hgb-206. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S64-S65.	2.0	7
48	Genome editing of HBG1 and HBG2 to induce fetal hemoglobin. <i>Blood Advances</i> , 2019, 3, 3379-3392.	2.5	121
49	2019 sickle cell disease guidelines by the American Society of Hematology: methodology, challenges, and innovations. <i>Blood Advances</i> , 2019, 3, 3945-3950.	2.5	14
50	Low-Dose Busulfan Reduces Human CD34+ Cell Doses Required for Engraftment in c-kit Mutant Immunodeficient Mice. <i>Molecular Therapy - Methods and Clinical Development</i> , 2019, 15, 430-437.	1.8	21
51	Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort study. <i>Lancet Haematology</i> , 2019, 6, e585-e596.	2.2	128
52	Ex vivo immunological evaluation of stable mixed chimeric patients after matched related donor allogeneic transplantation in sickle cell disease. <i>Cytotherapy</i> , 2019, 21, 1206-1215.	0.3	4
53	Transfusion support for matched sibling allogeneic hematopoietic stem cell transplantation (1993–2010): factors that predict intensity and time to transfusion independence. <i>Transfusion</i> , 2019, 59, 303-315.	0.8	12
54	Pain and opioid use after reversal of sickle cell disease following HLA-matched sibling haematopoietic stem cell transplant. <i>British Journal of Haematology</i> , 2019, 184, 690-693.	1.2	37

#	ARTICLE	IF	CITATIONS
55	Preclinical Evaluation for Engraftment of Gene-Edited CD34+ Cells with a Sickle Cell Disease Mutation in a Rhesus Transplantation Model. <i>Blood</i> , 2019, 134, 609-609.	0.6	2
56	Truncated Erythropoietin Receptors Confer an In Vivo Selective Advantage in Gene-Modified Erythroid Cells Expressing Fetal Hemoglobin Due to BCL11A Interference. <i>Blood</i> , 2019, 134, 2063-2063.	0.6	2
57	A Single Dose of CD117 Antibody Drug Conjugate Enables Autologous Gene-Modified Hematopoietic Stem Cell Transplant (Gene Therapy) in Nonhuman Primates. <i>Blood</i> , 2019, 134, 610-610.	0.6	14
58	Exploring the Drivers of Potential Clinical Benefit in Initial Patients Treated in the Hgb-206 Study of Lentiglobin for Sickle Cell Disease (SCD) Gene Therapy. <i>Blood</i> , 2019, 134, 2061-2061.	0.6	7
59	Resolution of Sickle Cell Disease Manifestations in Patients Treated with Lentiglobin Gene Therapy: Updated Results from the Phase 1/2 Hgb-206 Group C Study. <i>Blood</i> , 2019, 134, 990-990.	0.6	16
60	The Relationships between Target Gene Transduction, Engraftment of HSCs and RBC Physiology in Sickle Cell Disease Gene Therapy. <i>Blood</i> , 2019, 134, 206-206.	0.6	7
61	Durable and Robust Fetal Globin Induction without Anemia in Rhesus Monkeys Following Autologous Hematopoietic Stem Cell Transplant with BCL11A Erythroid Enhancer Editing. <i>Blood</i> , 2019, 134, 4632-4632.	0.6	6
62	Measuring Deformability and Red Cell Heterogeneity in Blood by Ektacytometry. <i>Journal of Visualized Experiments</i> , 2018, , .	0.2	25
63	Hematopoietic stem cell mobilization with plerixafor in sickle cell disease. <i>Haematologica</i> , 2018, 103, 749-750.	1.7	12
64	Robust erythroid differentiation system for rhesus hematopoietic progenitor cells allowing preclinical screening of genetic treatment strategies for the hemoglobinopathies. <i>Cytotherapy</i> , 2018, 20, 1278-1287.	0.3	6
65	Diagnostic challenges of prolonged post-treatment clearance of Plasmodium nucleic acids in a pre-transplant autospленectomized patient with sickle cell disease. <i>Malaria Journal</i> , 2018, 17, 23.	0.8	4
66	Serum-free Erythroid Differentiation for Efficient Genetic Modification and High-Level Adult Hemoglobin Production. <i>Molecular Therapy - Methods and Clinical Development</i> , 2018, 9, 247-256.	1.8	12
67	Gene therapy for sickle cell disease: An update. <i>Cytotherapy</i> , 2018, 20, 899-910.	0.3	84
68	Definitive Erythropoiesis from Pluripotent Stem Cells: Recent Advances and Perspectives. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1107, 1-13.	0.8	5
69	POGZ Is Required for Silencing Mouse Embryonic $\hat{1}^2$ -like Hemoglobin and Human Fetal Hemoglobin Expression. <i>Cell Reports</i> , 2018, 23, 3236-3248.	2.9	31
70	Stem cell transplantation in sickle cell disease: therapeutic potential and challenges faced. <i>Expert Review of Hematology</i> , 2018, 11, 547-565.	1.0	34
71	Outcomes for Initial Patient Cohorts with up to 33 Months of Follow-up in the Hgb-206 Phase 1 Trial. <i>Blood</i> , 2018, 132, 1080-1080.	0.6	11
72	Current Results of Lentiglobin Gene Therapy in Patients with Severe Sickle Cell Disease Treated Under a Refined Protocol in the Phase 1 Hgb-206 Study. <i>Blood</i> , 2018, 132, 1026-1026.	0.6	23

#	ARTICLE	IF	CITATIONS
73	Kinetic assay shows that increasing red cell volume could be a treatment for sickle cell disease. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E689-E696.	3.3	41
74	Bone Marrow as a Hematopoietic Stem Cell Source for Gene Therapy in Sickle Cell Disease: Evidence from Rhesus and SCD Patients. Human Gene Therapy Clinical Development, 2017, 28, 136-144.	3.2	23
75	RNA Trans-Splicing Targeting Endogenous β^2 -Globin Pre-Messenger RNA in Human Erythroid Cells. Human Gene Therapy Methods, 2017, 28, 91-99.	2.1	3
76	At least 20% donor myeloid chimerism is necessary to reverse the sickle phenotype after allogeneic HSCT. Blood, 2017, 130, 1946-1948.	0.6	119
77	Relationship between Mixed Donor Recipient Chimerism and Disease Recurrence after Hematopoietic Cell Transplantation for Sickle Cell Disease. Biology of Blood and Marrow Transplantation, 2017, 23, 2178-2183.	2.0	74
78	Vasopressin stimulates the proliferation and differentiation of red blood cell precursors and improves recovery from anemia. Science Translational Medicine, 2017, 9, .	5.8	26
79	Efficient Generation of β^2 -Globin-Expressing Erythroid Cells Using Stromal Cell-Derived Induced Pluripotent Stem Cells from Patients with Sickle Cell Disease. Stem Cells, 2017, 35, 586-596.	1.4	39
80	Immunohaematological complications in patients with sickle cell disease after haemopoietic progenitor cell transplantation: a prospective, single-centre, observational study. Lancet Haematology, 2017, 4, e553-e561.	2.2	24
81	Cyclophosphamide improves engraftment in patients with SCD and severe organ damage who undergo haploidentical PBSCT. Blood Advances, 2017, 1, 652-661.	2.5	84
82	Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study. PLoS Medicine, 2017, 14, e1002382.	3.9	107
83	Successful Plerixafor-Mediated Mobilization, Apheresis, and Lentiviral Vector Transduction of Hematopoietic Stem Cells in Patients with Severe Sickle Cell Disease. Blood, 2017, 130, 990-990.	0.6	16
84	Pain and Opioid Use after Reversal of Sickle Cell Disease Following Hematopoietic Stem Cell Transplant. Blood, 2017, 130, 970-970.	0.6	0
85	Total body irradiation must be delivered at high dose for efficient engraftment and tolerance in a rhesus stem cell gene therapy model. Molecular Therapy - Methods and Clinical Development, 2016, 3, 16059.	1.8	10
86	β^2 -Globin-Expressing Definitive Erythroid Progenitor Cells Generated from Embryonic and Induced Pluripotent Stem Cell-Derived Sacs. Stem Cells, 2016, 34, 1541-1552.	1.4	48
87	SENP1, but not fetal hemoglobin, differentiates Andean highlanders with chronic mountain sickness from healthy individuals among Andean highlanders. Experimental Hematology, 2016, 44, 483-490.e2.	0.2	13
88	Kinetics of lentiviral vector transduction in human CD34+ cells. Experimental Hematology, 2016, 44, 106-115.	0.2	7
89	Development of a New Generation, Forward-Oriented Therapeutic Vector for Hemoglobin Disorders. Blood, 2016, 128, 1172-1172.	0.6	2
90	Interim Results from a Phase 1/2 Clinical Study of Lentiglobin Gene Therapy for Severe Sickle Cell Disease. Blood, 2016, 128, 1176-1176.	0.6	42

#	ARTICLE	IF	CITATIONS
91	At Least 20% Donor Myeloid Chimerism Is Necessary to Reverse the Sickle Phenotype after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2016, 128, 2483-2483.	0.6	2
92	Discordance in lymphoid tissue recovery following stem cell transplantation in rhesus macaques: an in vivo imaging study. <i>Blood</i> , 2015, 126, 2632-2641.	0.6	15
93	Hydroxyurea-Increased Fetal Hemoglobin Is Associated with Less Organ Damage and Longer Survival in Adults with Sickle Cell Anemia. <i>PLoS ONE</i> , 2015, 10, e0141706.	1.1	43
94	Assessing Costs, Benefits, and Risks in Chronic Disease: Taking the Long View. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1149-1150.	2.0	7
95	Public titles of clinical trials should have ethics review. <i>Journal of Clinical Epidemiology</i> , 2015, 68, 1105-1107.	2.4	0
96	More Efficient Generation of β -Globin-Expressing Erythroid Cells Using Stromal Cell-Derived Induced Pluripotent Stem Cells. <i>Blood</i> , 2015, 126, 1150-1150.	0.6	0
97	Decitabine Suspends Human CD34+ Cell Differentiation and Proliferation during Lentiviral Transduction. <i>PLoS ONE</i> , 2014, 9, e104022.	1.1	4
98	Nonmyeloablative HLA-Matched Sibling Allogeneic Hematopoietic Stem Cell Transplantation for Severe Sickle Cell Phenotype. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 48.	3.8	277
99	TRIM5 β Variations Influence Transduction Efficiency With Lentiviral Vectors in Both Human and Rhesus CD34 + Cells In Vitro and In Vivo. <i>Molecular Therapy</i> , 2014, 22, 348-358.	3.7	26
100	No Impact of Lentiviral Transduction on Hematopoietic Stem/Progenitor Cell Telomere Length or Gene Expression in the Rhesus Macaque Model. <i>Molecular Therapy</i> , 2014, 22, 52-58.	3.7	4
101	HCT for Nonmalignant Disorders. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S6-S9.	2.0	4
102	Efficient transduction of human hematopoietic repopulating cells with a chimeric HIV1-based vector including SIV capsid. <i>Experimental Hematology</i> , 2013, 41, 779-788.e1.	0.2	14
103	Integration-specific In Vitro Evaluation of Lentivirally Transduced Rhesus CD34+ Cells Correlates With In Vivo Vector Copy Number. <i>Molecular Therapy - Nucleic Acids</i> , 2013, 2, e122.	2.3	20
104	Peripheral Blood As a Source Of Cells For Regenerative Medicine Applications In Sickle Cell Disease. <i>Blood</i> , 2013, 122, 2209-2209.	0.6	0
105	Generation Of Mature Erythroid Cells From Human Embryonic Stem Cell Derived Sacs and Optimization Of Erythroid Cell Generation. <i>Blood</i> , 2013, 122, 2425-2425.	0.6	4
106	Discordance Between Peripheral Blood and Tissue CD4+ Lymphocyte Reconstitution In Rhesus Monkeys Following Autologous Hematopoietic CD34+ Cell Transplantation: An In Vivo imaging Study. <i>Blood</i> , 2013, 122, 2019-2019.	0.6	2
107	Assessment Of The Endocrine Function Of Patients With Sickle Cell Disease After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2013, 122, 4646-4646.	0.6	1
108	CD34+CXCR4(CD184)+ Cells Differentiate Into Myeloid Dendritic Cell Progenitors. <i>Blood</i> , 2013, 122, 4835-4835.	0.6	0

#	ARTICLE	IF	CITATIONS
109	Hematopoietic Progenitor Cell Mobilization In Response To G-CSF Is More Robust In Healthy African American Compared To Caucasian Donors. <i>Blood</i> , 2013, 122, 696-696.	0.6	1
110	High-efficiency Transduction of Rhesus Hematopoietic Repopulating Cells by a Modified HIV1-based Lentiviral Vector. <i>Molecular Therapy</i> , 2012, 20, 1882-1892.	3.7	33
111	Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans. <i>Blood</i> , 2012, 120, 3635-3646.	0.6	222
112	Lentiviral Transduction Efficiency for Human CD34+ Cells Is Affected by TRIM5 Expression and Cell Proliferation. <i>Blood</i> , 2012, 120, 4220-4220.	0.6	0
113	Acquired Hemophilia A in an African-American Male After Stem Cell Transplant for Sickle Cell Disease: Successful Treatment with Recombinant Porcine Factor VIII (OBI-1) and Tolerance Induction with Rituximab and Prednisone. <i>Blood</i> , 2012, 120, 4631-4631.	0.6	0
114	Characterization of Early Lymphocytes Emerging After Nonmyeloablative Conditioning and Hematopoietic Stem Cell Transplant Supported with Sirolimus. <i>Blood</i> , 2012, 120, 4150-4150.	0.6	2
115	Prostaglandin E2 Enhances Human Cord Blood Stem Cell Xenotransplants and Shows Long-Term Safety in Preclinical Nonhuman Primate Transplant Models. <i>Cell Stem Cell</i> , 2011, 8, 445-458.	5.2	250
116	Allogeneic hematopoietic stem cell transplantation for sickle cell disease: the time is now. <i>Blood</i> , 2011, 118, 1197-1207.	0.6	121
117	Accelerated lymphocyte reconstitution and long-term recovery after transplantation of lentiviral-transduced rhesus CD34+ cells mobilized by G-CSF and plerixafor. <i>Experimental Hematology</i> , 2011, 39, 795-805.	0.2	34
118	Chicken HS4 Insulators Have Minimal Barrier Function Among Progeny of Human Hematopoietic Cells Transduced With an HIV1-based Lentiviral Vector. <i>Molecular Therapy</i> , 2011, 19, 133-139.	3.7	36
119	The Assessment of Human Erythroid Output in NOD/SCID Mice Reconstituted with Human Hematopoietic Stem Cells. <i>Cell Transplantation</i> , 2010, 19, 1465-1473.	1.2	13
120	5% Dimethyl sulfoxide (DMSO) and pentastarch improves cryopreservation of cord blood cells over 10% DMSO. <i>Transfusion</i> , 2010, 50, 2158-2166.	0.8	37
121	Long-Term Vector Integration Site Analysis Following Retroviral Mediated Gene Transfer to Hematopoietic Stem Cells for the Treatment of HIV Infection. <i>PLoS ONE</i> , 2009, 4, e4211.	1.1	15
122	Transient <i>In Vivo</i> β -Globin Production After Lentiviral Gene Transfer to Hematopoietic Stem Cells in the Nonhuman Primate. <i>Human Gene Therapy</i> , 2009, 20, 563-572.	1.4	12
123	Allogeneic Hematopoietic Stem-Cell Transplantation for Sickle Cell Disease. <i>New England Journal of Medicine</i> , 2009, 361, 2309-2317.	13.9	381
124	Development of a Human Immunodeficiency Virus Type 1-Based Lentiviral Vector That Allows Efficient Transduction of both Human and Rhesus Blood Cells. <i>Journal of Virology</i> , 2009, 83, 9854-9862.	1.5	53
125	Busulfan Produces Efficient Human Cell Engraftment in NOD/LtSz- <i>Scid</i> IL2R β - <i>Null</i> Mice. <i>Stem Cells</i> , 2009, 27, 175-182.	1.4	60
126	Granulocyte colony-stimulating factor (G-CSF) administration in individuals with sickle cell disease: time for a moratorium?. <i>Cytotherapy</i> , 2009, 11, 464-471.	0.3	105

#	ARTICLE	IF	CITATIONS
127	Mixed haematopoietic chimerism for sickle cell disease prevents intravascular haemolysis. <i>British Journal of Haematology</i> , 2007, 139, 504-507.	1.2	52
128	Low-dose parenteral busulfan provides an extended window for the infusion of hematopoietic stem cells in murine hosts. <i>Experimental Hematology</i> , 2007, 35, 1415-1420.	0.2	26
129	Factors Affecting Allogeneic Peripheral Blood Stem Cell Mobilization in a Large, Ethnically, Diverse Population.. <i>Blood</i> , 2007, 110, 3283-3283.	0.6	0
130	A genetic strategy to treat sickle cell anemia by coregulating globin transgene expression and RNA interference. <i>Nature Biotechnology</i> , 2006, 24, 89-94.	9.4	114
131	Busulfan pharmacokinetics, toxicity, and low-dose conditioning for autologous transplantation of genetically modified hematopoietic stem cells in the rhesus macaque model. <i>Experimental Hematology</i> , 2006, 34, 132-139.	0.2	34
132	Low-Dose Radiation Plus Rapamycin Promotes Long-Term Bone Marrow Chimerism. <i>Transplantation</i> , 2005, 80, 1541-1545.	0.5	33
133	Cloning and Functional Analysis of the Rhesus Macaque ABCG2 Gene: Forced Expression Confers an SP Phenotype among Hematopoietic Stem Cell Progeny in Vivo.. <i>Blood</i> , 2004, 104, 3219-3219.	0.6	1
134	Multiple Integration Events into Several Putative Oncogenes Was Required To Cause Leukemogenesis in Two Primate Recipients of RCR Contaminated Stem-Cells.. <i>Blood</i> , 2004, 104, 2102-2102.	0.6	3
135	Mobilization, collection, and processing of peripheral blood stem cells in individuals with sickle cell trait. <i>Blood</i> , 2002, 99, 850-855.	0.6	70
136	Late complications following treatment for severe aplastic anemia (SAA) with high-dose cyclophosphamide (Cy): follow-up of a randomized trial. <i>Blood</i> , 2002, 100, 4668-4670.	0.6	56
137	Transduction of hematopoietic stem cells in humans and in nonhuman primates. <i>Stem Cells</i> , 1997, 15, 135-140.	1.4	28
138	Severe thrombocytopenia in patients treated with suramin: Evidence for an immune mechanism in one. , 1996, 51, 152-157.		10
139	Allogeneic hematopoietic cell transplants for sickle cell disease. , 0, , 524-530.		0